The Rapid Influenza Diagnostic Tests Market is slated to witness exponentiation going forward. The IoMT (Internet-of-Medical-Things) is already transforming every walk of life, including healthcare. Healthcare IT has let both – patients and doctors carry/download information about each other anywhere and anytime through their smartphones/tabs. In other words, more connectivity translates to better access to data, thereby rendering better healthcare for patients. This would be the future of the healthcare vertical in the upcoming period.

Diagnosis of infectious diseases such as influenza is seeing a sea change owing to technological innovations and development of next-generation molecular tests such as Nuclear Acid Amplification Tests (NAATs) and advanced immunoassays. The global rapid influenza diagnostic tests market size will witness robust expansion at over 8% CAGR during the forecast period (2019 – 2029).

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/31040

Conventional immunoassays tend to be limited by their sensitivity and specificity, a shortcoming expected to be overcome through product innovation by key molecular diagnostics companies. Quidel and BD integrated electronic readers with immunoassays, to increase test sensitivity without switching to other expensive detection devices.

Company Profiles:

• SA Scientific
• 3M Company
• Abbott
• Becton, Dickinson & Company
• Biocartis N.V.
• BioFire Diagnostics (bioMerieux, Inc.)
• Biosynex S.A.
• Cepheid, Inc.
• Creative Diagnostics
• Focus Diagnostics (DiaSorin SpA)
• F. Hoffmann-La Roche
• GenMark Diagnostics
• Hologic, Inc.
• Luminex Corporation
• Meridian Bioscience, Inc.
• Princeton BioMeditech Corporation
• QIAGEN N.V.
• Quidel Corporation
• Sekisui Diagnostics
• Thermo Fisher Scientific, Inc.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/31040

Key Takeaways – Rapid Influenza Diagnostic Tests Market Study

• In the last few years, constant increase in demand for rapid point-of-care tests has prompted health-care providers to shift to rapid influenza diagnostic tests that can achieve results in 15 minutes or less.
• In terms of principle, immunochromatographic assays are expected to garner maximum share in the rapid influenza diagnostic tests market, which is attributable to its low cost and easy-to-use nature.
• Attributable to growing number of clinics, hospitals, and diagnostic centers, the global rapid influenza diagnostic tests market in North America is at the forefront and it is expected to remain most profitable region during the forecast period.
• South Asia is anticipated to be the fastest-growing region owing to high prevalence of seasonal flu and increasing preference to opt for diagnostic testing.

Considerable impact of global public health organizations in identifying effective flu management strategies coupled with rapid uptake of point-of-care diagnostic tools by primary care physicians are further augmenting the growth prospects for rapid influenza diagnostic tests market.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/31040

Strategic Expansion Strategies of Leading Players Shaping Market

Prominent molecular diagnostics vendors are focusing on establishing long-term supply relationships with diagnostic centers and other testing facilities. They are emphasizing more on increasing their sales force and entering into strategic partnerships with local suppliers and distributors to expand product reach. For instance, Cardinal Health collaborated with Qiagen to distribute the company’s molecular diagnostic products to smaller and mid-sized U.S. hospitals.

According to the American Hospital Association, there are around 5,000 community hospitals in the U.S., and this share is anticipated to grow exponentially due to substantial growth projections for players in the rapid influenza diagnostic tests market. Moreover, the rapid influenza diagnostic tests market is expected to witness significant growth, which is attributed to a robust pipeline of innovative products.

Know More About the Report

Persistence Market Research offers a unique perspective and actionable insights on rapid influenza diagnostic tests in its latest study, presenting historical demand assessment from 2014 – 2018 and projections from 2019 – 2029 on the basis of principle (immunochromatographic assays, immunofluorescence assays and nucleic acid amplification test (NAAT)), type (influenza A test, influenza B test and influenza A+B test), sample type (throat swab, nasal swab, nasal aspirate, nasal wash, nasopharyngeal swab, nasopharyngeal aspirate, nasopharyngeal wash and others) and end user (hospitals, diagnostic centers, nursing homes, office-based settings, urgent care centers, retail pharmacy clinics, schools & universities, public health camps and others (cruise ships, correctional facilities, etc.) in seven prominent regions.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]
Website – https://www.persistencemarketresearch.com